NOTCH1 and leukemia: Taking advantage of the spectrum of Notch1 mutations observed in the thymus-transplantation model, we tested the anti-tumor activity of therapeutic mAb against leukemias characterized by Notch1 5′ deletions, HD- and PEST-domain mutations.